![conference banner](/images/conference-banner.jpeg)
摘要
家族性地中海热(FMF)是一种罕见的常染色体隐性遗传性自身炎症性疾病,包括先天性免疫并且几乎完全影响地中海起源的人口。临床表现包括发热、白细胞增多反复发作、浆膜炎(腹膜炎、胸膜炎、关节炎)、肌痛或丹毒样皮肤病变,持续12-72小时。MEFV基因突变在染色体16p13.3编码异常PYRIN(marenostrin),异常表达的蛋白质的粒细胞、单核细胞、浆膜、滑膜成纤维细胞和参与激活caspase-1和处理及炎性β释放IL-1。自1972第一次报告,三环中性生物碱与秋水仙碱维持治疗,保留了对FMF患者的所有症状的治疗效果,因为它减少了疾病的活动性和防止发展继发性淀粉样变性和肾损害。辅助治疗包括非甾类化合物的秋水仙碱抗炎药和糖皮质激素。在一个小组或不能耐受秋水仙碱的秋水仙碱耐药FMF病人,选择性的治疗必须考虑。不断发展的经验都集中在生物制剂的潜在效能作为TNF-α抑制剂(依那西普英夫利昔单抗),白介素IL-1(rilonacept),IL-1抑制剂(anakinra canakinumab)和IL-6受体抗体(tocilizumab)。干扰素-α和沙利度胺也可用于FMF病人。然而,临床试验常常主要是不受控制和限制的案例,因此需要明确的结论。在罕见的FMF病中,旧的和新的治疗方法都被进行了讨论。我们需要知道,任何理想的治疗必须经得起时间的考验。
关键词: 阿那白滞素,自身炎症性疾病,人抗IL-β单克隆抗体,秋水仙素,染色体16p,依那西普,白细胞介素1,炎性体,利洛纳塞,继发性淀粉样变性。
Current Medicinal Chemistry
Title:Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare
Volume: 23 Issue: 1
Author(s): P. Portincasa
Affiliation:
关键词: 阿那白滞素,自身炎症性疾病,人抗IL-β单克隆抗体,秋水仙素,染色体16p,依那西普,白细胞介素1,炎性体,利洛纳塞,继发性淀粉样变性。
摘要: Familial Mediterranean Fever (FMF) is a rare autosomal recessive autoinflammatory disorder involving the innate immunity and affecting almost exclusively populations with Mediterranean origin. Clinical features include recurrent episodes of fever, leukocitosis, serositis (peritonitis or pleuritis, arthritis), myalgia or erysipelas-like skin lesions, lasting 12-72 hrs. The MEFV gene mutations on chromosome 16p13.3 encodes the abnormal pyrin (marenostrin), a protein expressed in granulocytes, monocytes, serosal and synovial fibroblasts and involved in the activation of caspase-1 and the processing and release of active pro-inflammatory IL-1β. Since the first report in 1972, maintenance therapy with colchicine, a tricyclic neutral alkaloid, remains the mainstay of treatment in symptomatic FMF patients since it reduces the disease activity and prevents the development of secondary amyloidosis and renal damage. Adjunctive symptomatic therapy to colchicine includes nonsteroideal antinflammatory drugs and corticosteroids. In a small group of colchicine-intolerant or colchicine-resistant FMF patients, alternative treatments must be considered. Evolving experiences have focussed on the potential effectiveness of biologic agents working as TNF-α inhibitors (etanercept, infliximab), IL-1 trap (Rilonacept), IL-1 inhibitors (Anakinra, Canakinumab) and IL-6 receptor antibody (Tocilizumab). Interferon-α and thalidomide have also been employed in FMF patients. Still, clinical trials are mainly uncontrolled and restricted to few cases, thus requiring definitive conclusions. Old, and new treatments are discussed in the rare FMF disease, with the concept that any ideal treatment has to stand the test of time.
Export Options
About this article
Cite this article as:
P. Portincasa , Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare, Current Medicinal Chemistry 2016; 23 (1) . https://dx.doi.org/10.2174/0929867323666151117121706
DOI https://dx.doi.org/10.2174/0929867323666151117121706 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lesson from the Pandemic: People should Always Stay Physically Active
Current Cardiology Reviews Organoid Models of Heart Diseases: Find a New Channel in Improvements of Cardiac Regenerative Medicine
Current Medicinal Chemistry Forceps: Still an Option?
Current Women`s Health Reviews Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Why do Athletes Develop Very Severe or Fatal Forms of COVID after Intense Exercise Following SARS-CoV-2 Infection or Anti-COVID Vaccination?
Infectious Disorders - Drug Targets COVID-19 Treatment Success After Repeat Courses of Azithromycin: A Report of Three Cases
Infectious Disorders - Drug Targets Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design Management of Adult Active Tuberculosis Disease in Era of HIV Pandemic, Current Practices and Future Perspectives
Infectious Disorders - Drug Targets In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
Current Pharmaceutical Design Cardiomyopathy of Pregnancy
Current Women`s Health Reviews Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Epigenetic Multiple Modulators
Current Topics in Medicinal Chemistry Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry Tuberculosis Treated by Multiple Drugs: An Overview
Current Drug Delivery From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Mixed Connective Tissue Disease (MCTD) and Undifferentiated Connective Tissue Disease (UCTD)
Current Rheumatology Reviews Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis
Current Pharmaceutical Biotechnology Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Infrequent Infections in COPD
Current Respiratory Medicine Reviews